Literature DB >> 23084532

The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.

Mario A Eisenberger1, Emmanuel S Antonarakis.   

Abstract

This article reviews the initial experience with chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) and outlines some of the ongoing clinical trials in this area. In addition, the authors outline current knowledge on outcomes of patients treated with taxane-based chemotherapy on retrospective analysis of randomized trials. These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23084532      PMCID： PMC3742094          DOI： 10.1016/j.ucl.2012.07.012

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  32 in total

Review 1.  Chemotherapy in patients with castration-resistant prostate cancer.

Authors:  Hielke J Meulenbeld; Paul Hamberg; Ronald de Wit
Journal:  Eur J Cancer       Date:  2009-09       Impact factor: 9.162

2.  Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.

Authors:  G Hudes; L Einhorn; E Ross; A Balsham; P Loehrer; H Ramsey; J Sprandio; M Entmacher; W Dugan; R Ansari; F Monaco; M Hanna; B Roth
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

3.  Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

Authors:  Stéphane Oudard; Eugeniu Banu; Philippe Beuzeboc; Eric Voog; Louis Marie Dourthe; Anne Claire Hardy-Bessard; Claude Linassier; Florian Scotté; Adela Banu; Yvan Coscas; François Guinet; Marie-France Poupon; Jean-Marie Andrieu
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

4.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

5.  Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.

Authors:  W Kreis; D R Budman; J Fetten; A L Gonzales; B Barile; V Vinciguerra
Journal:  Ann Oncol       Date:  1999-01       Impact factor: 32.976

Review 6.  Recent progress in management of advanced prostate cancer.

Authors:  Philip Kantoff
Journal:  Oncology (Williston Park)       Date:  2005-04       Impact factor: 2.990

7.  A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.

Authors:  Andrew J Armstrong; Elizabeth S Garrett-Mayer; Yi-Chun Ou Yang; Ronald de Wit; Ian F Tannock; Mario Eisenberger
Journal:  Clin Cancer Res       Date:  2007-11-01       Impact factor: 12.531

8.  Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.

Authors:  Tomasz M Beer; Christopher W Ryan; Peter M Venner; Daniel P Petrylak; Gurkamal S Chatta; J Dean Ruether; Kim N Chi; James Young; W David Henner
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

9.  Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.

Authors:  D R Berthold; G R Pond; R de Wit; M Eisenberger; I F Tannock
Journal:  Ann Oncol       Date:  2008-05-16       Impact factor: 32.976

Review 10.  Chemotherapy in hormone-refractory prostate cancer.

Authors:  Ronald de Wit
Journal:  BJU Int       Date:  2008-03       Impact factor: 5.588
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.